研究单位：[1]Suzhou Transcenta Therapeutics Co., Ltd.[2]Bristol-Myers Squibb[3]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China[4]Beijing Cancer Hospital,Beijing,Beijing,China,100036[5]Beijing Friendship Hospital, Capital Medical University,Beijing,Beijing,China[6]Peking Union Medical College Hospital,Beijing,Beijing,China[7]Peking University International Hospital,Beijing,Beijing,China[8]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China[9]Fujian Cancer Hospital,Fuzhou,Fujian,China[10]Fujian Medical University Union Hospital,Fuzhou,Fujian,China[11]The First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China[12]The Sixth Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,China[13]The People's Hospital of Guangxi Zhuang Autonomous Region,Guangxi,Guangxi,China[14]Hainan Provincial People''s Hospital,Haikou,Hainan,China[15]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Heibei,China[16]Harbin Medical University Cancer Hospital,Ha''erbin,Heilongjiang,China[17]Henan Cancer Hospital,Zhengzhou,Henan,China[18]Hubei Cancer Hospital,Wuhan,Hubei,China[19]Zhongnan Hospital of Wuhan University,Wuhan,Hubei,China[20]Hunan Cancer Hospital,Changsha,Hunan,China[21]Xiangya Hospital, Central South University,Changsha,Hunan,China[22]Suzhou Municipal Hospital,Suzhou,Jiangsu,China[23]The Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China[24]Xuzhou Central Hospital,Xuzhou,Jiangsu,China[25]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China[26]Jilin Cancer Hospital,Chang chun,Jilin,China[27]The First Hospital of Jilin University,Chang chun,Jilin,China[28]The First Affiliated Hospital of Jinzhou Medical University,Jinzhou,Liaoning,China[29]Liaoning Cancer Hospital & Institute,Shenyang,Liaoning,China[30]The First Hospital of China Medical University,Shenyang,Liaoning,China[31]Jinan Central Hospital,Jinan,Shandong,China[32]Linyi Cancer Hospital,Linyi,Shandong,China[33]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China[34]Fudan University Shanghai Cance Center,Shanghai,Shanghai,China[35]Zhongshan Hospital Fudan University,Shanghai,Shanghai,China[36]West China Hospital, Sichuan University,Chendu,Sichuan,China[37]Sichuan Cancer Hospital,Chengdu,Sichuan,China[38]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China[39]Tianjin Medical University General Hospital,Tianjin,Tianjin,China[40]First Affiliated Hospital of Zhejiang University,Hangzhou,Zhejiang,China[41]The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,China[42]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China
研究目的：
This is an open-label, multi-center, Phase I trial of TST001. Subjects with locally advanced or metastatic solid tumors will be enrolled. The study will consist of two parts: Part A is dose escalation and dose expansion phase for mono-therapy, and Part B is dose escalation and dose expansion phase for combination therapy in gastric, gastroesophageal junction(G/GEJ) and biliary tract cancer, etc.
